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Abstract
The subcutaneous ICD (S-ICD) represents an important advancement in defi-
brillation therapy that obviates the need for a transvenous lead, the most frequent 
complication with transvenous devices. The S-ICD has been shown similarly safe 
and effective as transvenous ICD therapy, but the two devices are not interchange-
able. The S-ICD is only suitable for patients who do not require bradycardia or anti-
tachycardia pacing functionality. In patients with underlying diseases associated 
with polymorphic ventricular tachycardia and a long life expectancy, an S-ICD may 
be the preferred choice. Moreover, it is advantageous in the situation of increased 
risk of endocarditis, i.e., previous device system infection and immunosuppres-
sion, including hemodialysis. In patients with abnormal vascular access and/or 
right-sided heart structural abnormalities, it may be the only option. The S-ICD is 
bulkier, the battery longevity is shorter, and the device cost is higher, even though 
remote follow-up is possible. A two- or three-incision implant procedure has been 
described with a lateral placement of the device and a single subcutaneous lead. The 
rate of inappropriate therapy for both S-ICD and transvenous systems is similar, but 
S-ICD inappropriate shocks are more frequently attributable to oversensing, which 
can often be resolved with sensing adjustments.
Keywords: lead complications, subcutaneous ICD, sudden cardiac death, S-ICD, 
transvenous ICD, T-wave oversensing
1. Introduction
The subcutaneous implantable cardioverter defibrillator (S-ICD) offers an 
alternative rescue device for sudden cardiac death in the form of an implantable 
device that can offer defibrillation therapy without the need for a transvenous lead. 
Lead failure is the most frequent source of complication requiring surgical revision. 
Approximately 20% of transvenous leads fail within 10 years and extraction may 
lead to devastating complications, including death [1–5]. The S-ICD differs from 
conventional transvenous ICD systems in other important ways: an S-ICD requires 
no transvenous leads (the most frequent source of device complications) but S-ICDs 
do not offer bradycardia pacing, antitachycardia pacing, cardiac resynchronization, 
plus they have limited programmability. Approved in Europe in 2009, the S-ICD 
system (SQ-RX 1010, Boston Scientific, Natick, Massachusetts, USA) consists of 
a pulse generator and a tripolar defibrillation lead, both of which are implanted 
subcutaneously. In terms of size, weight, and footprint, the S-ICD device is larger 
and heavier than a conventional transvenous ICD (approximately 130 vs. 60 g, 
respectively).
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S-ICDs are indicated for primary and secondary prevention but are seen as 
particularly useful for primary-prevention patients with a long life expectancy. The 
selection of an S-ICD system over a transvenous ICD may be based on a variety of 
factors. Transvenous ICD patients who experience device-related complications, 
such as lead problems, may be revised to an S-ICD device. In a German multicenter 
study, 25% of S-ICD patients had a previous transvenous system explanted because 
of device complications [6].
2. Implant techniques and considerations
The S-ICD system is composed of a tripolar parasternal lead, positioned to the 
left (about 1–2 cm) and parallel to the sternal midline; this lead plugs into the pulse 
generator, which is implanted over the fifth to sixth rib and positioned submuscularly 
between the midaxillarly and anterior axillary lines. The lead has three electrodes, two 
of which sense only. The defibrillation electrode is positioned between the two sens-
ing electrodes. The sensing vector is created from the sensing electrode to the can, 
with the device automatically selecting the better electrode for the vector to assure 
optimal sensing. Device implantation may require minimal (to verify final position) 
to no fluoroscopy, as much of the technique relies on anatomical landmarks [7].  
See Figure 1.
A three-incision technique (plus pocket formation) was originally pioneered for 
S-ICD implantation, and a newer two-incision approach has been described in the 
literature [8]. The two-incision approach creates an intermuscular pocket for the 
pulse generator rather than a subcutaneous pocket by incising the inframammary 
crease at the anterior border of the latissimus dorsi, allowing the generator to fit 
between the two muscles. Then a small incision at the xiphoid process (in the same 
direction as pocket incision) allows an electrode insertion device to tunnel the lead 
in place [8, 9]. In a study of 36 patients, the two-incision approach was found to 
be safe and effective and it may produce superior cosmetic results compared to the 
three-incision approach [9]. See Figure 2.
Figure 1. 
The S-ICD device is implanted over the fifth to sixth rib and to the side; the parasternal lead senses the 
subcutaneous ECG and automatically determines which of two sensing vectors to use (top or bottom electrode to 
can). (Artwork by Todd Cooper, courtesy of Jo Ann LeQuang).
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The time required for device implantation has been recently reported as an 
average of 68 ± 20 minutes which includes intraoperative defibrillation threshold 
(DT) testing [10]. DT testing is of decreasing importance with transvenous ICDs 
but remains a much-discussed topic for S-ICD systems. Guidelines still recommend 
DT testing during S-ICD implantation, even though it is often used without intra-
operative testing based on generalized findings from transvenous systems [11–13]. 
In a study of 98 S-ICD patients, 25% of patients failed to convert their induced 
arrhythmia with the first intraoperative 65 joule shock, necessitating further 
therapy delivery and/or external defibrillation. In this study, 24/25 patients could be 
successfully defibrillated following either reversal of shocking polarity or lead repo-
sition although the desired 10 joules safety margin could not be achieved in 4/24 
of these patients [14]. This suggests the importance of perioperative DT testing. 
However, 100% of patients could be converted from defibrillation with an internal 
80 joule shock [14]. In a subsequent study of 110 consecutive S-ICD patients, 50% 
(n = 55) did not undergo defibrillation testing at implant for any of several reasons 
(including patient condition, age, and physician preference). In this group, 11% had 
episodes of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) 
necessitating therapy delivery and all of them were effectively converted with the 
first 80 joule shock [15]. Ventricular tachycardia is a rhythm disorder originating in 
the heart’s lower chambers that has a rate of at least 100 beats per minute; ventricu-
lar fibrillation is a much faster, chaotic heart rhythm that causes the heart to quiver 
rather than pump effectively. Thus, the notion that DT testing at implant is neces-
sary for S-ICD patients has been challenged.
S-ICD implantation may be carried out under local anesthesia [16], conscious 
sedation, or general anesthesia (64.1% of U.S. implants of S-ICD systems [17]. 
The rate of complications at implant is low and the most commonly reported 
Figure 2. 
Lateral view of a patient with an implanted S-ICD. (Courtesy of Dr. Peter Magnusson with permission of 
patient.).
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complication is infection (1.8%) [18]. By dispensing with the transvenous leads, 
the S-ICD system avoids periprocedural and complications associated with con-
ventional transvenous defibrillation leads, i.e. pericardial effusion, pneumothorax, 
accidental arterial puncture, nerve plexus injury, and tricuspid valve damage [19].
3. Safety and efficacy of S-ICDs
S-ICDs appear to have similar rates of infection and other complications as 
transvenous systems and to be similarly effective in rescuing patients from sudden 
cardiac death, but there are important distinctions between the two systems.
3.1 Safety
In a retrospective study of 1160 patients who received an implantable defibrilla-
tor (either transvenous system or S-ICD) at two centers in the Netherlands, patients 
were analyzed using propensity matching to yield 140 matched patient pairs. The 
rates of complications, infection, and inappropriate therapy were statistically 
similar between groups, but S-ICD patients had significantly fewer lead-related 
complications than the transvenous group (0.8 vs. 11.5%, p = 0.030) and more 
non-lead-related complications (9.9 vs. 2.2%, p = 0.047) [20]. The most frequently 
reported S-ICD complication involved device sensing.(20) Pooled data from the 
Investigational Device Exemption (IDE) and postmarket registry EFFORTLESS 
(n = 882) found S-ICD-related complications occurred at a rate of 11.1% at 3 years, 
but with no lead failures, S-ICD-related endocarditis, or bacteremia [21]. An IDE 
allows a device that is the subject of a clinical study to be used to collect data about 
safety and effectiveness that may be later used to submit to the U.S. Food and Drug 
Administration (FDA). Device-related complications were more frequent with 
transvenous systems when compared to S-ICD devices in a propensity-matched 
case–control study of 69 S-ICD and 69 transvenous ICD patients followed for a mean 
of 31 ± 19 or 32 ± 21 months, respectively. About 29% of transvenous ICD patients 
experienced a device-related complication compared to 6% of S-ICD patients, reduc-
ing the risk of complications for S-ICD patients by 70%; transvenous lead problems 
were the most frequently reported complication in the former group [22].
In the largest study of S-ICD patients (n = 3717) to date, complications were low 
at 1.2% overall. The most frequently reported complications were cardiac arrest 
(0.4%), hematoma (0.3%), death (0.3%), lead dislodgement (0.1%), myocardial 
infarction (0.1%), and hemothorax (<0.1%) [23]. Device revision during index 
hospitalization was infrequent (0.1%) [23]. Infections occur at roughly similar 
rates with S-ICD and transvenous systems but with the important distinction that 
S-ICD infections may sometimes be resolved with conservative therapy (course 
of antibiotics with device left in place), whereas most transvenous ICD infections 
necessitate the extraction of the device and the transvenous leads. In a survey from 
the U.K. reporting on data from 111 S-ICD patients, 11/111 (10%) of patients expe-
rienced infection, of whom 6 could be successfully treated conservatively without 
device extraction [24]. The EFFORTLESS registry (n = 472) reported a 4% rate of 
documented or suspected infections and complication-free rates at 30 and 360 days 
were 97 and 94%, respectively [25].
Once implanted, the S-ICD device delivers a nonprogrammable, high-energy 
rescue shock (80 joules) to the thorax compared to shocks of 45 joules to the heart 
administered by conventional transvenous systems. Notably the S-ICD delivers a 
65 joule shock during implant testing. Therapy delivery differs markedly between 
S-ICD and transvenous systems in terms of the amount of energy delivered, location 
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of shocking vectors, and potential for damage to surrounding tissue or the heart. In 
a porcine study, the mean time to therapy delivery was significantly longer with an 
S-ICD than a transvenous system (19 vs. 9 seconds, p = 0.001) but the S-ICD shocks 
were associated with less elevation of cardiac biomarkers. The longer time to therapy 
may be advantageous in that device patients often experience short runs of non-
sustained VT. On the other hand, S-ICD shocks were associated with more skeletal 
muscle injuries than transvenous device shocks owing to the energy patterns resulting 
from the device placement but the clinical relevance of this is likely negligible [26].
3.2 Efficacy
Effective shock therapy is often defined as conversion of an episode of VT/
VF within five shocks, differing from effective first-shock therapy which occurs 
when the initial shock converts the arrhythmia. In a study of 79 S-ICD patients at 
a tertiary center, 7.6% of patients experienced at least one appropriate shock for a 
ventricular tachyarrhythmia during the follow-up period (mean 12.8 ± 13.7 months) 
[27]. In a multicenter study from Germany (n = 40), shock efficacy was 96.4% 
[95% confidence interval (CI), 12.8–100%] and first-shock efficacy was 57.9% (95% 
CI, 35.6–77.4%) [6]. In an effort to analyze S-ICD efficacy in a large group of diverse 
patients, data from the Investigation Device Exemption (IDE) clinical study and 
the EFFORTLESS post-market registry were pooled to provide information about 
882 patients followed for 651 ± 345 days. About 59 patients experienced therapy 
delivery for 111 spontaneous VT/VF episodes with first-shock efficacy in 90.1% 
of events and shock efficacy (termination with five or fewer shocks) in 98.2% of 
patients [21]. In the EFFORTLESS registry (n = 472), first-shock efficacy in discrete 
episodes of VT/VF was 88% and shock efficacy within five shocks was 100% [25].
4. Inappropriate shocks with S-ICDs
Inappropriate shock describes therapy delivery to treat an episode which the 
device inappropriately detects as a ventricular tachyarrhythmia. Inappropriate 
shocks have been recognized as a significant clinical challenge with transvenous 
systems as well as S-ICDs. In a tertiary care center study of 79 S-ICD patients, 
inappropriate shock occurred in 8.9% (n = 7) of patients, attributable to T-wave 
oversensing, atrial tachyarrhythmia with rapid atrioventricular conduction, exter-
nal interference and/or baseline oversensing due to lead movement [27]. T-wave 
oversensing occurs when the device inappropriately senses ventricular repolar-
izations (the T-waves on the electrocardiograph) counting them as ventricular 
events, leading to double counting of the intrinsic ventricular rate. In a multicenter 
German study (n = 40) with a median follow-up of 229 days, four patients (10%) 
experienced 21 arrhythmic episodes resulting in 28 therapy deliveries. Four of these 
episodes were inappropriately identified by the device as ventricular tachyarrhyth-
mias, with the result that two patients received inappropriate shocks. This results 
in a rate of 10% inappropriately detected ventricular tachycardia and 5% delivery 
of inappropriate therapy [6]. In a study using pooled data from the IDE and 
EFFORTLESS post-market registry (n = 882), the three-year rate for inappropriate 
therapy delivery was 13.1% [21].
It does not appear there are statistically more cases of inappropriate therapy in 
S-ICD patients compared to transvenous ICD patients. A propensity-matched study 
(69 patients with a transvenous ICD and 69 with an S-ICD) found the rate of inap-
propriate shocks was 9% in the transvenous and 3% in the S-ICD groups but this 
was not statistically significant (p = 0.49) [22]. In a study of 54 S-ICD patients in a 
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real-world prospective registry, the one-year rate for inappropriate therapy delivery 
was 17%, most of whom had single-zone programming [10].
Inappropriate shocks with S-ICDs may be minimized. Most of them are caused 
by T-wave oversensing. In a survey from the U.K. (n = 111 implanted patients 
covered), 24 appropriate shocks were delivered in 12% of the patients (n = 13) and 
51 inappropriate shocks were delivered in 15% of the patients (n = 17), of which 
80% could be traced to T-wave oversensing [24]. In the EFFORTLESS registry 
(n = 472), there was a 7% rate of inappropriate therapy delivery in 360 days, mainly 
due to oversensing [25]. The main causes of inappropriate therapy delivery have 
been reported to be supraventricular tachycardia (SVT) at a rate above the discrimi-
nation zone, T-wave oversensing, other types of oversensing (e.g. interference), 
SVT discrimination errors, and low-amplitude signals [21]. Inappropriate therapy 
delivery due to T-wave oversensing can often be remedied by adjusting the sensing 
vector or adding another discrimination zone (dual-zone programming) [10].
Certain patients may be at elevated risk for inappropriate shock. A single-center 
study of 18 hypertrophic cardiomyopathy (HCM) patients implanted with an S-ICD 
system and followed for a mean 31.7 ± 15.4 months concluded that HCM patients 
may be at elevated risk for T-wave oversensing which could lead to inappropriate 
therapy delivery. In this study, 39% of these HCM patients had T-wave oversens-
ing and 22% of the study population (n = 4) experienced inappropriate therapy 
delivery [28]. An evaluation of 581 S-ICD patients found that inappropriate shocks 
caused by oversensing occurred in 8.3% of S-ICD patients and patients with HCM 
and/or a history of atrial fibrillation were at elevated risk for inappropriate therapy 
[29]. There is a paucity of data on the use of S-ICD devices in HCM patients, but 
a small study of 27 HCM patients screened for possible S-ICD therapy found 85% 
(n = 23) were deemed appropriate candidates and 15 had the device implanted [30]. 
At implant testing, all patients were successfully defibrillated with a 65 joules shock 
and most induced arrhythmias were terminated with a 50 joules shock (12/15). 
After the median follow-up period of 17.5 months (range 3–35 months), there were 
no appropriate shocks and one inappropriate shock, attributed to oversensing 
caused when the QRS amplitude was reduced while the patient bent forward. In this 
particular high-risk patient group of HCM patients without a pacing indication, the 
S-ICD was effective at detecting and terminating tachyarrhythmias [30].
5. Mortality
The mortality risk with S-ICD implantation is low, but merits scrutiny. On 
the one hand, S-ICD implantation is generally associated with fewer risks than 
transvenous ICD implantation in that no transvenous leads are required. On the 
other hand, patient selection for S-ICD may favor more high-risk patients (such as 
those with a prior infection, renal failure, comorbid conditions such as diabetes) 
but also includes many younger and generally fitter patients. Overall, mortality 
data from S-ICD studies appears favorable. In a pooled analysis combining IDE 
data and EFFORTLESS registry information, the one-year and two-year mortality 
rates were 1.6 and 3.2%, respectively [21]. In a study of real-world use of S-ICDs in 
54 primary- and secondary-prevention patients, mortality at the mean follow-up 
duration of 2.6 ± 1.9 years was 11% but no patient died of sudden cardiac arrest 
[10]. In a six-month study comparing 91 S-ICD and 182 single-chamber transvenous 
ICD patients, mortality rates were similar although the S-ICD patients had more 
severe pre-existing illness at implant [31]. It may be that the similar mortality rates 
between transvenous and S-ICD populations reflects the patient populations rather 
than the implantation procedure or device characteristics [23].
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6. Troubleshooting S-ICDs
The S-ICD device was designed to be a streamlined system with fewer than 10 
programmable features (transvenous ICDs have over 100 programmable features) 
and to perform in a largely automated fashion in terms of device function. The 
recent introduction of dual-zone programming to S-ICDs added a degree of pro-
grammability and reduced inappropriate shock [32]. Arrhythmia detection in the 
S-ICD relies on a system of template matching, based on waveform morphology of 
the subcutaneous ECG obtained at implant [33]. Oversensing and sensing-related 
problems are the most frequently reported problems but are being addressed in 
terms of device design and programmability. T-wave oversensing occurs when the 
device incorrectly identifies a T-wave as a QRS complex and counts it as a native 
ventricular beat, which leads to double-counting the rate. The use of dual-zone 
device programming has reduced the incidence of inappropriate therapy as a result 
of double-counting caused by T-wave oversensing [34]. T-wave inversions and 
QRS complexes that are overly large or very small may be particularly vulnerable 
to sensing anomalies. Reprogramming the sensing vector or therapy zones may 
be helpful in such instances [35, 36]. In a propensity-matched study comparing 
transvenous ICDs to S-ICDs, there were three inappropriate shocks in the S-ICD 
group, all of which were due to T-wave oversensing in sinus rhythm and all of which 
could be eliminated with adjustment of the sensing vector [22]. Furthermore, it 
has been observed with increasing operator experience and better programming 
techniques, sensing problems have been reduced [21]. In a study using pooled data 
from the IDE and EFFORTLESS registry, the rate of inappropriate therapy associ-
ated with oversensing was <1% [21]. When inappropriate shock occurs, the stored 
electrograms will likely help identify the cause. If lead malposition is suspected, a 
chest X-ray may be appropriate. In case of oversensing, the sensing vector may be 
optimized, device programming may be revised to add a second detection zone, or 
pharmacological therapy may be added [32].
SVT discrimination likewise relies on template-matching (which is similar to 
transvenous systems) but the S-ICD may be able to accomplish this with a higher 
degree of resolution than transvenous ICDs [33]. The use of dual-zone program-
ming appears advantageous.
7. Primary and secondary prevention
Primary- and secondary-prevention patients represent two distinct patient 
populations who may be treated with S-ICD therapy, although S-ICDs seem 
particularly well suited for primary-prevention patients. Secondary-prevention 
patients have a lower rate of comorbid conditions and significantly higher left-ven-
tricular ejection fractions (LVEF) than primary-prevention patients (48 vs. 36%, 
p < 0.0001), while primary-prevention patients had a higher incidence of heart 
failure and were more likely to have had a transvenous ICD implanted before the 
S-ICD. Primary-prevention patients also have a higher rate of ischemic cardiomy-
opathy (41 vs. 33%) and nonischemic cardiomyopathy (28 vs. 12%) [18]. S-ICDs 
have been shown to be effective for both primary- and secondary-prevention 
patients. In a study of 856 S-ICD patients (mean follow-up 644 days), there were 
no significant differences between primary- and secondary-prevention popula-
tions in the rates of effective arrhythmia conversions, inappropriate therapy, 
mortality or complications although appropriate therapy delivery was delivered to 
significantly more secondary-prevention than primary prevention patients (11.9 
vs. 5.0%, p = 0.0004) [18].
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The freedom from any appropriate therapy delivery was 88.4% among primary-
prevention patients with an LVEF ≤35 and 96.2% among primary-prevention 
patients with an LVEF >35%. The freedom from any appropriate therapy delivery 
among secondary-prevention patients was 92.1% [18]. Spontaneous conversion to 
sinus rhythm was more frequent among primary-prevention patients (about 48% 
of all ventricular tachyarrhythmias) compared to secondary-prevention patients 
(31%) [18]. However, the rates of inappropriate therapy delivery and complications 
were similar for both primary- and secondary-prevention patients [18].
8. The optimal candidates for S-ICD
S-ICD systems are indicated for patients who require rescue defibrillation but do 
not need bradycardia pacing support and would not benefit from antitachycardia 
pacing or cardiac resynchronization therapy. This includes primary- and secondary-
prevention patients. By avoiding transvenous leads, the S-ICD is particularly 
appropriate for patients with occluded veins or limited venous access (who are not 
suitable candidates for transvenous systems) and the S-ICD may be beneficial for 
younger, fitter, and active patients. The generator position of the S-ICD patient may 
make it easier and safer for strong, fit patients to resume active lifestyles without 
jeopardizing lead position.
Despite the fact that S-ICD devices are larger than transvenous systems, their 
lateral placement may result in more pleasing esthetic results than a conventional 
transvenous ICD. Young device patients likely will have a lifetime of device therapy, 
resulting over time in much hardware in their vasculature; the S-ICD thus presents 
an advantage in that regard. It appears that S-ICDs are implanted in a younger 
patient population; a survey of multiple U.K. hospitals (n = 111 patients) found the 
median patient age was 33 (range 10–87 years) [24]. The mean age of patients in the 
EFFORTLESS registry was 49 ± 18 years (range 9–88 years) [25]. Younger patients 
with cardiomyopathy or channelopathy often have a high rate of complications with 
conventional transvenous ICDs [37] and it has been thought they may be better 
served with an S-ICD device [9].
In a multicenter case–control study, it was found that 59.4% of S-ICD patients were 
primary-prevention and the main underlying cardiac conditions were dilated cardio-
myopathy (36.2%), ischemic cardiomyopathy (15.9%), and HCM (14.5%) [38]. In 
particular, these patients have been considered challenging to treat with a conventional 
transvenous ICD in that they may have an erratic electrical substrate in the heart and 
increased left-ventricular mass, which could contribute to an elevated DT. First-shock 
efficacy rates of up to 88% are promising in light of these challenges [25]. In a study 
of 50 hypertrophic cardiomyopathy patients implanted with S-ICDs, 96% of patients 
could be induced to an arrhythmia at implant and of the 73 episodes of VF induced, 
98% were successfully converted with 65 joules from the S-ICD during DT testing. 
One patient in this study (2%) required rescue external defibrillation [39]. The patient 
who failed internal defibrillation had a body mass index of 36 and was successfully 
converted by an 80 joules shock with reversed polarity from the S-ICD [39].
9. Current guidelines
9.1 Indications
The most recent guidelines to address S-ICD were published by the American 
Heart Association, the American College of Cardiology, and the Heart Rhythm 
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Society in 2017 [40]. The An S-ICD is indicated (Class of Recommendation 1, level 
of evidence B) for patients who meet indication criteria for a transvenous ICD but 
who have inadequate vascular access or are at high risk of infection and for whom 
there is no anticipated need for bradycardia or antitachycardia pacing. Further, 
implantation of an S-ICD is deemed reasonable for patients with an ICD indication 
for whom there is no anticipated need for bradycardia or antitachycardia pacing 
(Class of Recommendation IIa, level of evidence B). An S-ICD is contraindicated in 
a patient who is indicated for bradycardia pacing, antitachycardia pacing for termi-
nation of ventricular tachyarrhythmias, and/or cardiac resynchronization therapy 
(Class of Recommendation III, level of evidence B) [40].
The European Society of Cardiology guidelines from 2015 report that S-ICDs are 
effective in preventing sudden cardiac death and the device is recommended as an 
alternative to transvenous ICDs in patients who are indicated for defibrillation but 
not pacing support, cardiac resynchronization therapy, or antitachycardia pacing 
(Class IIa, Level C). Moreover, the S-ICD was considered to be a useful alternative 
for patients in whom venous access was difficult or for patients who had a trans-
venous system explanted because of an infection or for young patients expected to 
need long-term ICD therapy [41].
9.2 Pre-implant testing
Those considered for S-ICD therapy should be screened with a modified ver-
sion of the three-channel surface electrocardiogram (ECG) set up to represent the 
sensing vectors of the S-ICD. With the patient both standing and supine, the ratio 
of R-wave to T-wave should be established and signal quality evaluated. If any of 
the three vectors does not result in satisfactory sensing, the S-ICD should not be 
implanted. Once the actual device is implanted in the patient, the system automati-
cally selects the optimal sensing vector [11].
9.3 Programming
The S-ICD may be programmed to detect arrhythmias using a single- or dual-
zone configuration. In the dual-zone configuration, a lower cutoff rate defines what 
might be called a “conditional shock zone” to which a discrimination algorithm is 
applied so that therapy is withheld if the rhythm might be deemed supraventricular 
in origin or non-arrhythmic oversensing. This discrimination zone relies on a form 
of template matching. Above that rate, a cutoff establishes the “shock zone” which 
delivers a shock based on the rate criterion alone. When the capacitors charge in 
anticipation of shock delivery, a confirmation algorithm assures the persistence of 
the arrhythmia prior to sending the shock. Shocks are delivered at the nonprogram-
mable 80 joules of energy [11].
10. Future directions
The evolution of the S-ICD adds an important new device into the armamen-
tarium for rescuing patients from sudden cardiac death. To further improve S-ICD 
technology, size reduction, increased battery longevity, and improved T-wave 
rejection will be needed. In the near future, improvement in sensing function might 
eliminate the need for a separate screening ECG prior to implant, which could 
optimize clinical workflow.
Improved battery technology is particularly important as the S-ICD is often used 
in patients with a relatively long life expectancy. Leadless pacemaker systems that 
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might work together with an S-ICD are in development which would allow for bra-
dycardia pacing support, antitachycardia pacing and a subcutaneous defibrillator 
without transvenous leads [32]. The development of a leadless epicardial pacemaker 
might allow for left-atrial and left-ventricular pacing function to be integrated to 
the S-ICD. Taken altogether, these improvements could make the S-ICD the pre-
ferred device in the vast majority of cases for rescue from sudden cardiac death.
11. Conclusion
The subcutaneous implantable cardioverter defibrillator (S-ICD) offers an 
alternative to transvenous ICDs but the two systems should not be considered 
interchangeable. The S-ICD is appropriate for patients who require only rescue 
defibrillation (primary or secondary prevention) but does not offer bradycardia 
pacing, antitachycardia pacing, overdrive pacing, or cardiac resynchronization 
therapy. S-ICD devices may be appropriate in patients who have occluded vascula-
ture or device infection with a transvenous system. Effectiveness, rate of infections, 
and survival rates are similar for both devices although, in general, S-ICDs may be 
implanted in patients with more serious underlying conditions such as end-stage 
renal disease or advanced diabetes. Infections with S-ICDs are more likely to be 
effectively treated with a conservative course of antibiotic therapy and no device 
extraction. Inappropriate shocks occur at similar rates with both systems but are 
more likely caused by oversensing in the S-ICD. A main advantage of S-ICDs over 
transvenous systems is the elimination of the transvenous defibrillation lead which 
may be considered the Achilles heel of the transvenous system, having a 10-year 
complication rate of 25%. It is likely that considerable advances in ICD therapy will 
occur in the next decade as the S-ICD systems are further refined.
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